Enter multiple symbols separated by commas

BioCryst Shares Plunge on Disappointing Drug Data

BioCryst Pharmaceuticals announced disappointing results of a mid-stage clinical trial for its bird flu treatment peramivir, sending shares down sharply in after-hours trading.

The Birmingham, Ala.-based company said preliminary results from a Phase II clinical trial of influenza patients were not statistically significant.

The stock was down at $7.60 in electronic trade after closing on the Nasdaq at $11.78.

Contact Stocks


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.